
Morgan Hakki

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/2976713/publications.pdf Version: 2024-02-01



#	Article	IF	CITATIONS
1	Real-Life Use of Ceftolozane/Tazobactam for the Treatment of Bloodstream Infection Due to Pseudomonas aeruginosa in Neutropenic Hematologic Patients: a Matched Control Study (ZENITH) Tj ETQq1	10.7 84 814	rgBīT1/Overlo
2	Emergence of non-susceptibility during persistent <i>Pseudomonas aeruginosa</i> bacteraemia in haematopoietic cell transplant recipients and haematological malignancy patients. JAC-Antimicrobial Resistance, 2021, 3, dlab125.	2.1	3
3	Letermovir treatment of cytomegalovirus infection or disease in solid organ and hematopoietic cell transplant recipients. Transplant Infectious Disease, 2021, 23, e13687.	1.7	34
4	American Society for Transplantation and Cellular Therapy Series: #3—Prevention of Cytomegalovirus Infection and Disease After Hematopoietic Cell Transplantation. Transplantation and Cellular Therapy, 2021, 27, 707-719.	1.2	45
5	Isavuconazole Prophylaxis in Patients With Hematologic Malignancies and Hematopoietic Cell Transplant Recipients. Clinical Infectious Diseases, 2020, 70, 723-730.	5.8	73
6	Toxoplasmosis in nonâ€cardiac solid organ transplant recipients: A case series and review of literature. Transplant Infectious Disease, 2020, 22, e13218.	1.7	10
7	Moving Past Ganciclovir and Foscarnet: Advances in CMV Therapy. Current Hematologic Malignancy Reports, 2020, 15, 90-102.	2.3	27
8	lsavuconazole to prevent invasive fungal infection in immunocompromised adults: Initial experience at an academic medical centre. Mycoses, 2019, 62, 665-672.	4.0	29
9	Incidence and Outcomes of Bacterial Bloodstream Infections during Acute Graft-versus-Host Disease Involving the Gastrointestinal Tract after Hematopoietic Cell Transplantation. Biology of Blood and Marrow Transplantation, 2019, 25, 1648-1653.	2.0	5
10	Fluoroquinolone Prophylaxis Selects for Meropenem-nonsusceptible Pseudomonas aeruginosa in Patients With Hematologic Malignancies and Hematopoietic Cell Transplant Recipients. Clinical Infectious Diseases, 2019, 68, 2045-2052.	5.8	43
11	Ceftolozane-tazobactam therapy for multidrug-resistant Pseudomonas aeruginosa infections in patients with hematologic malignancies and hematopoietic-cell transplant recipients. Infection, 2018, 46, 431-434.	4.7	25
12	<i>Coccidioides immitis</i> Cervical Lymphadenitis Complicated by Esophageal Fistula. Case Reports in Infectious Diseases, 2016, 2016, 1-4.	0.5	3
13	The clinical impact of coronavirus infection in patients with hematologic malignancies and hematopoietic stem cell transplant recipients. Journal of Clinical Virology, 2015, 68, 1-5.	3.1	30
14	Differential Properties of Cytomegalovirus pUL97 Kinase Isoforms Affect Viral Replication and Maribavir Susceptibility. Journal of Virology, 2014, 88, 4776-4785.	3.4	26
15	Predictive Value of Testing Nasopharyngeal Samples for Respiratory Viruses in the Setting of Lower Respiratory Tract Disease. Journal of Clinical Microbiology, 2014, 52, 4020-4022.	3.9	22
16	Effects on maribavir susceptibility of cytomegalovirus UL97 kinase ATP binding region mutations detected after drug exposure in vitro and in vivo. Antiviral Research, 2012, 95, 88-92.	4.1	27
17	Resistance to maribavir is associated with the exclusion of pUL27 from nucleoli during human cytomegalovirus infection. Antiviral Research, 2011, 92, 313-318.	4.1	13
18	Long-Term Dominance of Carbapenem-Non-Susceptible Pseudomonas aeruginosa ST111 in Hematologic Malignancy Patients and Hematopoietic Cell Transplant Recipients. Frontiers in Cellular and Infection Microbiology, 0, 12, .	3.9	6